Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $284.56 | $28,456.00 |
DisclosureSEC source: 0001209191-20-042492 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,692 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $284.56 (range $284.37 to $284.74). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $90.29 | $77,649.40 |
DisclosureSEC source: 0001209191-20-042492 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 47 | $288.04 | $13,537.88 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $288.04 (range $287.77 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14 | $287.00 | $4,018.00 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,979 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $287.00 (range $286.76 to $287.75). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $285.51 | $5,710.20 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,993 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $285.51 (range $285.37 to $285.64). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $282.85 | $2,828.50 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,013 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $281.81 | $5,636.20 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,023 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $281.81 (range $281.62 to $282.00). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30 | $279.89 | $8,396.70 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,043 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $279.89 (range $279.42 to $280.19). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $275.71 | $2,757.10 |
DisclosureSEC source: 0001209191-20-030487 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,073 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 611 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · derivative · entry 11 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,281 Underlying: Common Stock · 611 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 465 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,122 Underlying: Common Stock · 465 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 70 | $275.17 | $19,261.90 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred5 at a weighted average price of $275.17 (range $275.07 to $275.30). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 210 | $274.41 | $57,626.10 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,002 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred5 at a weighted average price of $274.41 (range $274.05 to $274.65). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $273.53 | $65,647.20 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,212 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $273.53 (range $273.03 to $273.90). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 328 | $272.40 | $89,347.20 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,452 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $272.40 (range $272.03 to $272.98). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 149 | $270.51 | $40,305.99 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,780 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $270.51 (range $270.00 to $270.75). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 79 | $269.41 | $21,283.39 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,929 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $269.41 (range $268.97 to $269.87). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 611 | $155.57 | $95,053.27 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 465 | $187.53 | $87,201.45 |
DisclosureSEC source: 0001209191-20-027904 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · derivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,427 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 59 | $264.75 | $15,620.25 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $264.75 (range $264.59 to $264.89). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $262.83 | $26,283.00 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,991 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $262.83 (range $262.74 to $262.92). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $261.55 | $52,310.00 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,091 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $261.55 (range $261.13 to $262.11). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 250 | $259.97 | $64,992.50 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,291 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $259.97 (range $259.72 to $260.33). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $259.21 | $51,842.00 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,541 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $259.21 (range $258.62 to $259.60). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-20-027476 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 859 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860 Underlying: Common Stock · 859 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 166 | $252.26 | $41,875.16 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $252.26 (range $251.99 to $252.85). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 193 | $250.29 | $48,305.97 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,098 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $250.29 (range $249.95 to $250.54). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $248.96 | $37,344.00 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,291 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $248.96 (range $248.75 to $249.30). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $247.18 | $37,077.00 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,441 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $247.18 (range $246.88 to $247.44). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $245.62 | $36,843.00 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $245.62 (range $245.31 to $246.00). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 50 | $244.09 | $12,204.50 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,741 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 859 | $90.29 | $77,559.11 |
DisclosureSEC source: 0001209191-20-024476 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,891 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-023914 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,892 Underlying: Common Stock · 4,891 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,891 | $255.57 | $1,249,992.87 |
DisclosureSEC source: 0001209191-20-023914 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,891 | $155.57 | $760,892.87 |
DisclosureSEC source: 0001209191-20-023914 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $238.40 | $35,760.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.40 (range $238.19 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 90 | $236.85 | $21,316.50 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,082 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.65 to $237.24). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $235.49 | $35,323.50 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,172 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.49 (range $235.15 to $235.87). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $234.50 | $35,175.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,322 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.50 (range $234.14 to $235.10). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $232.40 | $27,888.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,472 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.40 (range $232.37 to $232.44). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 137 | $231.17 | $31,670.29 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,592 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.17 (range $230.73 to $231.47). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 283 | $229.66 | $64,993.78 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,729 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.66 (range $229.20 to $230.14). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 864 | $239.23 | $206,694.72 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,012 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 202 | $245.74 | $49,639.48 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,876 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.74 (range $245.55 to $245.86.) Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 280 | $245.00 | $68,600.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,078 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.00 (range $244.52 to $245.43.) Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 202 | $243.85 | $49,257.70 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,358 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.85 (range $243.52 to $244.29). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 640 | $242.80 | $155,392.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,560 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.80 (range $242.45 to $243.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $241.95 | $58,068.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.95 (range $241.43 to $242.40). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.